Complete title: A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-targeted Chimeric Antigen Receptor (CAR)-Modified T cells Bearing a Human Binding Domain, in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia
| Research Study Number | 9364 |
| Principal Investigator | Cameron Turtle, PhD, MBBS |
| Phase | I |
Other eligibility criteria may apply.
| Research Study Number | 9364 |
| Contact | Seattle Cancer Care Alliance Intake Office |
| Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Immune System Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.